Unichem Labs gets USFDA nod for hypertension drug Guanfacine

Published On 2021-03-05 06:31 GMT   |   Update On 2023-10-13 10:51 GMT

Mumbai: Drugmaker, Unichem Laboratories Limited, has recently announced that the company has received abbreviated new drug application (ANDA) approval for its Guanfacine Tablets, USP 1 mg and 2 mg from the United States Food and Drug Administration (USFDA) to market a generic version of TENEX (Guanfacine) Tablets 1 mg and 2 mg of Promius Pharma LLC.

Guanfacine Tablets are indicated in the management of hypertension.
The product will be commercialized from Unichem's Ghaziabad Plant.

Read also: Unichem Labs plaque psoriasis drug Apremilast gets USFDA nod

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company.

It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News